Comments
Venus Remedies Limited, a leading research-based global pharmaceutical company announces positive Top-Line results in the Phase-3 Clinical Trials for its flagship product ELORES. The results were presented at IDWeek 2018 in San Francisco. IDWeek is an annual scientific meeting of the Infectious Diseases Society of America (IDSA). Companys four abstracts were accepted for poster presentations at the IDWeek 2018. These posters covered the efficacy results from the plea clinical trial, as well as supportive in vitro efficacy data from an AMR Surveillance study. Plea Clinical trial is a multi-center, randomized, double-blind Phase 3 trial designed to evaluate the safety and efficacy of ELORES (Ceftriaxone + Sulbactam + EDTA) versus Meropenem for the treatment of complicated Urinary Tract Infections (cUTI) and Acute Pyelonephritis (AP). The results of the plea Clinical Trial include analysis of the primary outcomes which were defined as per the FDA & EMA guidance. Saransh Chaudhary, CEO, Venus Medicine Research Centre said plea trial is Indias first Phase-3 clinical trial of such design in the anti-infective space and we are proud to be the first Indian company to have conducted this study & present the results at the worlds largest infectious diseases event, IDWeek 2018. We believe that this will further nourish Indian research ecosystem and help in putting Indian innovations on the global research landscape." Elores is a novel, patented critical care antibiotic combination targeting unmet medical needs in Antimicrobial Resistance (AMR) space. The global demand for antibiotics has grown significantly over the past two decades. The global antibiotics market was valued at about USD 40.86 billion in 2017, which is estimated to register a CAGR of 4.7%, over the period, 2018 to 2023. After successful representation at ID Week, October 2018 at San Francisco, Elores was launched in three important Latin American markets i.e. Colombia, Dominican Republic, Guatemala and is scheduled to be launched in Saudi Arabia on the 23rd of this month. These international launches will bring in significant revenue over the next 3-5 years and help the Company in strengthening its position in the Middle-Eastern and Latin American markets. Elores is now available in 7 countries, with scheduled launches in another 4 territories over the next year. Elores is under registration in many parts of world.
Source : BSE - www.bseindia.com
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.